Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction- SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity (STRUCTURE)

Back

ESC Premium Access

Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction- SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity (STRUCTURE)

Session: Drug therapy in heart failure

Topic: Diastolic dysfunction

Speaker: Professor W. Kosmala (Wroclaw, PL)

Event: ESC Congress 2016

Congress Presentation

About the speaker

Professor Wojciech Kosmala

Wroclaw Medical University, Wroclaw (Poland)

3 presentations

1 follower

4 more presentations in this session

State of the art in drug therapy in chronic heart failure.

Speaker: Professor D. van Veldhuisen (Groningen, NL)

Access

Slides

Video

Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registr

Speaker: Doctor G. Savarese (Stockholm, SE)

Risk of long-term mortality associated with diuretic treatment in 17,519 heart failure outpatients was increased with 42% after adjustment for MAGGIC mortality risk predictors

Speaker: Doctor P. Paren (Gothenburg, SE)

Access

Abstract

Future direction for research in drug therapy.

Speaker: Professor J. Teerlink (San Francisco, US)

Access

Slides

Video

Access the full session

Drug therapy in heart failure

Speakers: Professor W. Kosmala, Professor D. van Veldhuisen, Doctor G. Savarese, Doctor P. Paren, Professor J. Teerlink

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction- SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity (STRUCTURE)

About the speaker

Professor Wojciech Kosmala

4 more presentations in this session

State of the art in drug therapy in chronic heart failure.

Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registr

Risk of long-term mortality associated with diuretic treatment in 17,519 heart failure outpatients was increased with 42% after adjustment for MAGGIC mortality risk predictors

Future direction for research in drug therapy.

Access the full session

Drug therapy in heart failure

About the event

ESC Congress 2016

ESC 365 is supported by